GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Debt-to-Asset

Abbisko Cayman (HKSE:02256) Debt-to-Asset : 0.01 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Debt-to-Asset?

Abbisko Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$12.2 Mil. Abbisko Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$20.9 Mil. Abbisko Cayman's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was HK$2,431.6 Mil. Abbisko Cayman's debt to asset for the quarter that ended in Jun. 2024 was 0.01.

Abbisko Cayman Debt-to-Asset Historical Data

The historical data trend for Abbisko Cayman's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Debt-to-Asset Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
0.03 0.01 0.02 0.02 0.02

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only 0.02 0.02 0.02 0.02 0.01

Competitive Comparison of Abbisko Cayman's Debt-to-Asset

For the Biotechnology subindustry, Abbisko Cayman's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Debt-to-Asset falls into.


Abbisko Cayman Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Abbisko Cayman's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(11.605 + 27.469) / 2313.76
=0.02

Abbisko Cayman's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(12.2 + 20.943) / 2431.594
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman  (HKSE:02256) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Abbisko Cayman Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Debt-to-Asset
Comparable Companies
HKSE:02137 HKSE:02181 HKSE:01672 HKSE:06628 HKSE:02496 HKSE:06978 HKSE:06622 HKSE:01875 HKSE:01873 HKSE:09939 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
8ZD:Germany
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Website
https://www.abbisko.com
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Xu Yao-chang 2101 Beneficial owner
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited 2301 Trustee
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines